MAPT and Insulin resistance: Since brain insulin resistance and subsequent brain glucose hypometabolism, tau pathology, and neuroinflammation might occur simultaneously in AD patients, a therapeutic strategy that could collectively alleviate these unfavorable pathological changes will be useful in AD treatment.